Conference Presentation, Panel, Fireside Chat
Medical Marijuana: Health and (Financial) Wellness
- Ghost Vapes plans to launch its first vaporizer in early June to advance medical cannabis research, while Mary's Medicinals currently operates in eight states and anticipates expansion to twelve.
- States with legal medical marijuana programs report 25% fewer opiate-related deaths, supporting a thesis that the marijuana industry is a $70 billion market today with only $4 billion legal, where conversion from illegal to legal operations is expected to accelerate growth.
- Ben Kovler predicts that 35, 36, or 37 states, representing 70% of all states, will reach a tipping point for legalization, while California, the sixth-largest economy, is expected to see enormous commerce with a coherent banking system currently being established.
- The gray markets in states like California and Michigan are predicted to be over, with a shift driven by a "tidal wave" of demand including new organic growth and consumers switching from pharmaceuticals like oxycontin and Ambien.
- International expansion opportunities include a potential $12 billion market in Germany, Brazil, Mexico, Argentina, and Uruguay, where countries are legalizing medical consumption, though administrative barriers to cross-border import-export remain a significant challenge.
- In the long term, 15 to 20 years out, the "Marlboro of cannabis" is predicted to emerge as the sector's biggest company, and by 5 to 10 years, cannabis is expected to become an international commodity produced at low cost by specialized countries.
- Juan Sartori forecasts that within three to five years, several cannabis companies will reach a $10 billion valuation, driven by the current market size exceeding capacity and the ability of the largest growers to ramp up production quickly.
- The CBD and hemp market, utilized for pain relief, is projected to be four times the size of the current medical marijuana market, with investment in biotech clinical trials and patenting expected to be highly profitable over the next 18 to 24 months as sub-sectors break out.
- Canada's market is described as far from saturation with current production capacity of less than 40 tons against an estimated demand of 500 tons, while 72 other cannabinoids like CBN for PTSD are identified as having significant unexplored medicinal benefits.
- Institutional investment is currently hindered by federal illegality, creating an opportunity for private investors to enter at favorable valuations, although the industry faces risks regarding the long-term survival of growers without low-cost advantages or regulatory protections.
- The stigma surrounding cannabis is expected to be eliminated as the narrative shifts to highlight that cannabis has caused zero fatalities compared to over 30,000 pill-related deaths in the US last year, potentially influencing adoption by groups like the NFL Retired Players Association representing 22,000 players.
- Pharma companies are anticipated to dominate the CBD market through patents or low-cost production, while the broader industry offers a marriage of capitalism and altruism through capital inflows driven by state financial needs and high growth potential.